Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 6/20 | 0.46 |
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | CTRC | Q99895 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
| ▸ | BAD | Q92934 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29129885 | 0.88 | TP53 (0.57) | TSHRRAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL181195 | 0.85 | NAPRT (0.40) | NAPRTRAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL8110752 | 0.78 | RAB9A (0.50) | RXRARXRBTSHRRAB9ANPC1 | |
| SCHEMBL28680918 | 0.78 | RAB9A (0.45) | TSHRRAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL18653550 | 0.76 | LDHA (0.51) | TSHRRAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL9254659 | 0.76 | LMNA (0.47) | ALDH1A1 | |
| SCHEMBL2314305 | 0.76 | MAPT (0.45) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL13458074 | 0.76 | SMN1; SMN2 (0.47) | RAB9ANPC1SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL180516 | 0.76 | POLB (0.39) | KDM4EPOLB | |
| SCHEMBL240423 | 0.76 | RAB9A (0.50) | RAB9ANPC1SMN1; SMN2KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150065517-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| US-8912208-B2 | (4-{4-[5-(benzooxazol-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid useful for treating or preventing conditions or disorders associated with DGAT1 activity | NOVARTIS AG (CH) | 2014-12-16 | — | — | US | disclosed |
| US-8835451-B2 | Compounds | NOVARTIS AG (CH) | 2014-09-16 | — | — | US | disclosed |
| EP-2418202-B1 | (4-[4-[5-(substituted amino)-pyridin-2-yl]phenyl]-cyclohexyl)-acetic acid derivatives as DGAT inhibitors | NOVARTIS AG (CH) | 2014-01-29 | — | — | EP | disclosed |
| CN-103288721-A | (4-(4-[6-(trifluoromethyl-pyridin-3-ylamino)-n-containing-heteroaryl]-phenyl)-cyclohexyl)-acetic acid derivatives and pharmaceutical uses thereof | NOVARTIS AG | 2013-09-11 | — | — | CN | disclosed |
| CN-101415683-B | Novel compounds | NOVARTIS AG | 2013-07-17 | — | — | CN | disclosed |
| US-20130018074-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2013-01-17 | — | — | US | disclosed |
| US-20130018054-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2013-01-17 | — | — | US | disclosed |
| EP-2418202-A1 | New compounds | Novartis AG (CH) | 2012-02-15 | — | — | EP | disclosed |
| EP-2404905-A1 | New compounds | Novartis AG (CH) | 2012-01-11 | — | — | EP | disclosed |
| EP-2301923-A1 | New compounds | Novartis AG (CH) | 2011-03-30 | — | — | EP | disclosed |
| US-20090247534-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2009-10-01 | — | — | US | disclosed |
| CN-101415683-A | Novel compounds | NOVARTIS AG (CH) | 2009-04-22 | — | — | CN | disclosed |
| US-7504412-B2 | Imidazopyridine derivatives | BANYU PHARMACEUTICALS, CO., LTD. (JP) | 2009-03-17 | — | — | US | disclosed |
| EP-2004607-A2 | NEW COMPOUNDS | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| CN-100418965-C | Imidazopyridine derivatives | BANYU PHARMA CO LTD (JP) | 2008-09-17 | — | — | CN | disclosed |
| US-20080200494-A1 | Imidazopyridine Derivatives | MSD K.K. (JP) | 2008-08-21 | — | — | US | disclosed |
| WO-2007126957-A2 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2007-11-08 | — | — | WO | disclosed |
| CN-1835950-A | Imidazopyridine derivatives | BANYU PHARMA CO LTD (JP) | 2006-09-20 | — | — | CN | disclosed |
| EP-1657242-A1 | IMIDAZOPYRIDINE DERIVATIVES | Banyu Pharmaceutical Co., Ltd. (JP) | 2006-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065517-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | NAPRT 2127/4885RXRA 631/4885RXRB 670/4885 |
| US-20090247534-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | NAPRT 2127/4885RXRA 631/4885RXRB 670/4885 |
| US-20080200494-A1 | Imidazopyridine Derivatives | MC1R, MC3R, MC5R | NAPRT 3584/4885RXRA 972/4885RXRB 1157/4885 |
| US-20130018054-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | NAPRT 2136/4885RXRA 608/4885RXRB 638/4885 |
| US-20130018074-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | NAPRT 2136/4885RXRA 608/4885RXRB 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.